Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

ZED1227 is a small molecule tissue transglutaminase (TG2) inhibitor. The compound selectively binds to the active state of TG2, forming a stable covalent bond with the cysteine in its catalytic center. The molecule was designed for the treatment of celiac disease. Celiac disease is an autoimmune-med...

Full description

Bibliographic Details
Main Authors:	Christian Büchold, Martin Hils, Uwe Gerlach, Johannes Weber, Christiane Pelzer, Andreas Heil, Daniel Aeschlimann, Ralf Pasternack
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Cells
Subjects:	tissue transglutaminase transglutaminase inhibitor celiac disease drug discovery
Online Access:	https://www.mdpi.com/2073-4409/11/10/1667

Similar Items

Tissue Transglutaminase but Not Microbial Transglutaminase Is Inhibited by Exogenous Oxidative Substances in Celiac Disease
by: Sebastian Stricker, et al.
Published: (2022-02-01)

The Detection of Silent Celiac Disease In patients With Type 1 Diabetes Mellitus by the use of Anti Tissue Transglutaminase Antibodies
by: Anower Tuama Obaid, et al.
Published: (2012-06-01)

The Detection of Silent Celiac Disease In patients With Type 1 Diabetes Mellitus by the use of Anti Tissue Transglutaminase Antibodies
by: Anower Tuama Obaid, et al.
Published: (2012-12-01)

Anti-tissue transglutaminase antibodies and EEG pattern in celiac patients on prolonged gluten-free diet
by: A. Berio, et al.
Published: (2013-01-01)

Antibody Responses to Transglutaminase 3 in Dermatitis Herpetiformis: Lessons from Celiac Disease
by: Helka Kaunisto, et al.
Published: (2022-03-01)

Diagnostic accuracy of IgA anti-tissue transglutaminase antibody testing in celiac disease
by: Eremić Nevena, et al.
Published: (2012-01-01)

Effect of helicobacter pylori infection eradication on serum level of anti-tissue transglutaminase in children with celiac disease
by: Pejman Rohani, et al.
Published: (2023-03-01)

Development of celiac-safe foods: prevention of transglutaminase 2 (TG2) deamidation of gluten in healthy non-celiac volunteers
by: Niklas Engström, et al.
Published: (2024-03-01)

Celiac Disease-Type Tissue Transglutaminase Autoantibody Deposits in Kidney Biopsies of Patients with IgA Nephropathy
by: Rakel Nurmi, et al.
Published: (2021-05-01)

Separate Gut Plasma Cell Populations Produce Auto‐Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis
by: Saykat Das, et al.
Published: (2023-09-01)

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment
by: Jorma Isola, et al.
Published: (2023-06-01)

Clinical Value of Tissue Transglutaminase Antibodies in Celiac Patients over a Long Term Follow-Up
by: Elisa Farina, et al.
Published: (2021-08-01)

Changes in Non-Deamidated versus Deamidated Epitope Targeting and Disease Prediction during the Antibody Response to Gliadin and Transglutaminase of Infants at Risk for Celiac Disease
by: Ádám Diós, et al.
Published: (2022-02-01)

DIAGNOSTIC ACCURACY OF IGA ANTI-TISSUE TRANSGLUTAMINASE ANTIBODY IN THE DIAGNOSIS OF CELIAC DISEASE TAKING HISTOPATHOLOGY AS GOLD STANDARD
by: Munir Akmal Lodhi, et al.
Published: (2021-04-01)

Anti-Endomysial and Anti-Tissue Transglutaminase Serological Test Compared with Small Bowel Biopsy in the Diagnosis of Celiac Disease
by: M Shadman, et al.
Published: (2013-10-01)

Retrospective study of tissue transglutaminase antibody levels in celiac disease-suspected patients at tertiary care hospital in Uttarakhand
by: Swati Rajput, et al.
Published: (2021-01-01)

Microbial Transglutaminase Is Immunogenic and Potentially Pathogenic in Pediatric Celiac Disease
by: Matthias Torsten, et al.
Published: (2018-12-01)

The Effect of Xanthan, Guar and Transglutaminase on the Physicochemical and Textural Properties of Gluten-free Doughnut
by: Arezo Fazeli, et al.
Published: (2019-04-01)

Possible pathophysiological roles of transglutaminase-catalyzed reactions in the pathogenesis of human neurodegenerative diseases
by: Enrica Serretiello, et al.
Published: (2015-09-01)

The temperature and pH repertoire of the transglutaminase family is expanding
by: Aaron Lerner, et al.
Published: (2020-04-01)

Screening for Celiac Disease Using Anti Tissue Transglutaminase in Patients with Esophageal SCC between 2004 and 2009
by: Hasan Vosoughinia, et al.
Published: (2015-01-01)

Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages
by: Enzo Ierardi, et al.
Published: (2015-01-01)

Celiac Crisis
by: Rômulo Ribeiro do Vale, et al.
Published: (2018-08-01)

Survey of the initial management of celiac disease antibody tests by ordering physicians
by: Kathryn Potter, et al.
Published: (2019-07-01)

T Cell Response Toward Tissue-and Epidermal-Transglutaminases in Coeliac Disease Patients Developing Dermatitis Herpetiformis
by: Marzia Caproni, et al.
Published: (2021-04-01)

A celiac disease marker: Serum immunoglobulin a anti-tissue transglutaminase in vitiligo cases and controls in a hospital in South-West Nigeria
by: Adetokunbo O Ajala, et al.
Published: (2022-01-01)

HLA DQ2/DQ8 haplotypes and anti-transglutaminase antibodies as celiac disease markers in a pediatric population with type 1 diabetes mellitus
by: Diana Rita Oliveira, et al.
Published: (2022-04-01)

Screening for celiac disease among patients of the gastroenterological profile
by: S. V. Bykova, et al.
Published: (2021-02-01)

Aspectos genéticos e imunopatogênicos da doença celíaca: visão atual Genetics and immunopathogenics aspects of the celiac disease: a recent vision
by: Shirley Ramos da Rosa Utiyama, et al.
Published: (2004-06-01)

Prevalence of Celiac disease in north of Iran: Screening of an adult population in Sari
by: H.Tirgar-Fakheri (M.D), et al.
Published: (2004-03-01)

Don’t forget the exogenous microbial transglutaminases: it is immunogenic and potentially pathogenic
by: Aaron Lerner, et al.
Published: (2016-11-01)

Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies
by: Sebastian Stricker, et al.
Published: (2023-03-01)

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model
by: Berend van der Wildt, et al.
Published: (2018-05-01)

Celiac crisis, atypical form of celiac disease onset in teenager – a case report
by: Daniela Ciobanu, et al.
Published: (2020-12-01)

Transglutaminase 2 in human diseases
by: Szondy Zsuzsa, et al.
Published: (2017-09-01)

Evaluating the Correlation between High Titers of Tissue-Transglutaminase Antibody with the Grade of Severity of Villous Atrophy in Syrian Patients with Celiac Disease
by: A. Alhabbal, et al.
Published: (2022-05-01)

Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years
by: Anna Rita Di Biase, et al.
Published: (2021-11-01)

Diagnostic challenges in children with celiac disease. A five-year experience with new guidelines in a General Pediatrics Department
by: Daniela Pop, et al.
Published: (2023-03-01)

Prevalence of Tissue Transglutamase Antibodies in cases of Celiac Disease
by: Samreen Soomro, et al.
Published: (2015-04-01)

Prevalence of Tissue Transglutamase Antibodies in cases of Celiac Disease
by: Samreen Soomro, et al.
Published: (2015-04-01)